BHR BIOSYSNEX
Providing Point-of-care Solutions that meet the needs of an evolving NHS
Founded in 1990 as BHR Pharmaceuticals Ltd, BHR BIOSYNEX is a market leader in the provision of point-of-care diagnostics solutions. We specialise in sourcing advanced and progressive technology from around the world and deliver these innovative products to our customers in the UK & Ireland.
Our extensive range of products allows us to work differently to other point of care providers. Our experienced team of experts will listen to your specific requirements and work with you to tailor the best solution to your needs. We’d love to talk to you about the challenges you’re facing now and let’s see how we can help.
1 Kingfisher Court
Hemdale Business Park
Nuneaton, Warwickshire
CV11 6GY
T: +44 (0)2476 377210
BHR Pharmaceuticals Ltd
Company Reg No: 2460338
BHR Biosynex Appoints Adam Martin as UK & Ireland Country Manager
BHR Biosynex, a leading provider of point-of-care diagnostic solutions and trusted home-use healthcare products, is pleased to announce the appointment of Adam Martin as Country Manager for the UK & Ireland.
In his role, Adam will be responsible for leading BHR Biosynex’s commercial strategy across the UK and Ireland, overseeing continued growth across point-of-care testing solutions for healthcare professionals alongside the company’s expanding portfolio of home-use, self-care and OTC healthcare products. This includes supporting the ongoing introduction of additional Biosynex Pharma brands into the UK & Ireland market.
Adam brings extensive experience in healthcare sales leadership, market development and strategic partnership building, with a strong track record of driving growth across both professional healthcare and consumer health channels. His expertise spans working closely with clinical stakeholders, community pharmacy, distributors and commercial partners to successfully launch and scale innovative healthcare solutions.
BHR Biosynex is at an exciting stage of development, continuing to strengthen its position in point-of care diagnostics that support rapid clinical decision-making, while also responding to growing demand for accessible, high-quality home testing and self-care solutions that empower patients to take a more active role in managing their health. Commenting on the appointment, Oren Bitton, Deputy Chief Executive Officer at BIOSYNEX Group, said: “We are very happy to welcome Adam to BHR Biosynex. His leadership experience and understanding of both professional diagnostics and consumer healthcare make him an excellent fit for our ambitions in the UK & Ireland.
Adam’s appointment marks an important step as we enter the next chapter of the company’s history. I very much look forward to working with him as we build on our strong foundations and pursue the exciting growth opportunities ahead, across both point-of-care and home-use healthcare solutions.”
In his role, Adam will focus on strengthening customer and partner relationships, expanding BHR Biosynex’s footprint across healthcare, pharmacy and consumer channels, and supporting the successful introduction of new diagnostic and OTC innovations from the wider BIOSYNEX Group.
On joining the company, Adam Martin said: “I am proud to be joining such a great company at a pivotal time and to be leading such an experienced, incredible team. Point of care testing is being utilised across the UK and Ireland healthcare system in increasing varied locations and the addition of the OTC and self-test products compliments the offerings to both healthcare professionals and consumers. We are in for an exciting journey and thank you to Oren, and the UK and Ireland team for their warm welcome”.
BHR Biosynex Secures Exclusive UK Distribution of AFR-900 Fluorescence Immunoassay Analyser
Nuneaton, UK – 17 September 2025
BHR Biosynex is proud to announce an exclusive distribution agreement with Hangzhou AllTest Biotech Co. Ltd for the AFR-900 Fluorescence Immunoassay Analyser, bringing an innovative, compact point-of-care testing (POCT) solution to healthcare professionals across the UK.
The AFR-900 combines laboratory-level accuracy with true portability, making it an ideal solution for a wide range of care environments, from GP surgeries and community clinics to hospitals and ambulance services. Weighing less than 1.5 kg and equipped with a built-in battery, the analyser can be easily deployed wherever rapid, reliable results are needed.
Designed with healthcare professionals in mind, the AFR-900 delivers results in just 3–15 minutes, supporting faster clinical decision-making and improving patient flow. Its plug-and-play operation and intuitive 7-inch colour touch screen ensure ease of use with minimal training required, while seamless LIS compatibility enables straightforward data transfer. The system’s broad menu of tests covers key clinical areas including cardiac markers, inflammation, endocrinology, infectious diseases, and women’s health.
For patients, this means quicker answers, earlier interventions, and better outcomes - without the delays associated with central laboratory testing. By enabling clinicians to diagnose and manage conditions more efficiently, the AFR-900 helps to support improved standards of care and patient experience across diverse healthcare settings.
Wendy Thompson, Head of Marketing at BHR Biosynex, commented: “We are delighted to bring the AFR-900 to the UK market as part of our ongoing commitment to supporting healthcare professionals with innovative point-of-care testing solutions. This compact, versatile analyser offers both accuracy and speed, empowering clinicians to make timely decisions that directly benefit their patients.”
The exclusive distribution of the AFR-900 strengthens BHR Biosynex’s portfolio of advanced diagnostic solutions and underlines its position as a trusted partner in delivering high-quality, patient-focused innovations to the UK healthcare sector.
BHR Biosynex looks forward to showcasing the analyser on Stand 900 at the IBMS Congress in Birmingham, 22-25 September 2025, where healthcare professionals will be able to see live demonstrations and explore the system’s capabilities first-hand.
The main features and benefits of the AFR-900 Fluorescence Immunoassay Analyser include:
- Compact & Portable Design – lightweight (<1.5 kg) with a built-in battery, ideal for use in GP surgeries, clinics, hospitals, and ambulances.
- Rapid Results – delivers reliable answers in just 3–15 minutes, with reading time under 20 seconds.
- Ease of Use – intuitive 7-inch colour touch screen and simple plug-and-play operation requiring minimal training.
- Broad Clinical Coverage – wide test menu including cardiac, inflammatory, endocrine, infectious disease, and tumour markers.
- Seamless Connectivity – POCT-ready with LIS compatibility and built-in thermal printer for efficient data management.
- Consistent Accuracy – europium-based fluorescence technology with rigorous self-checks for dependable performance.
BHR Biosynex Announces Exclusive UK Distribution of the EHBT-50 Minilab Multi-Functional Analyser
Nuneaton, UK – 17 September 2025
BHR Biosynex is delighted to announce an exclusive UK distribution agreement with Hunan Ehome Health Technology Company Limited for the EHBT-50 Minilab Multi-Functional Analyser, an all-in-one diagnostic platform that brings together haematology, immunology, biochemistry, urine and faecal testing in a single compact device.
For healthcare professionals, the EHBT-50 enables faster, more efficient and cost-effective workflows across hospitals, laboratories, GP practices and community settings. For patients, it translates into quicker access to accurate results, earlier diagnosis, timely treatment decisions and smoother care pathways – helping to improve both outcomes and overall healthcare system efficiency.
BHR Biosynex is pleased to confirm that the EHBT-50 will launch in the UK with a fully validated NHS Hospital Protocol Template to support clinical adoption.
Wendy Thompson, Head of Marketing at BHR Biosynex, commented: “We are thrilled to bring the EHBT-50 Minilab to the UK healthcare market. This innovative analyser represents a major step forward in point-of-care diagnostics, offering clinicians a versatile, accurate and space-saving solution while improving the patient experience. At BHR Biosynex, we are committed to supporting UK healthcare professionals with the very best technology, and the EHBT-50 is a clear example of that commitment.”
BHR Biosynex looks forward to showcasing the analyser on Stand 900 at the IBMS Congress in Birmingham, 22-25 September 2025, where healthcare professionals will be able to see live demonstrations and explore the system’s capabilities first-hand.
About EHBT-50 Minilab Multi-Functional Analyser
The main features and benefits of the EHBT-50 Minilab Multi-Functional Analyser include:
- All-in-One Diagnostic Platform – combines haematology, immunoassay, biochemistry, urine and faecal testing in one compact system.
- Lab-Grade Accuracy – offers advanced 7-differential haematology with AI-powered morphology to detect and classify abnormal blood cells.
- Comprehensive Clinical Coverage – supports testing across a wide range of conditions including diabetes, anaemia, cardiac disease, thyroid disorders, fertility, inflammation, liver and renal function.
- Future-Proof Technology – expandable via over-the-air updates, ensuring continued clinical relevance.
- Streamlined Workflow – reduces turnaround times, optimises laboratory space and simplifies processes in both acute and primary care.
